Cardiac fibroblast-specific p38α MAP kinase promotes cardiac hypertrophy via a putative paracrine interleukin-6 signaling mechanism by Bageghni, SA et al.
1Cardiac fibroblast-specific p38 MAP kinase promotes cardiac hypertrophy via a
paracrine interleukin-6 signalling mechanism
Sumia A. Bageghni PhD1, Karen E. Hemmings PhD1, Ngonidzashe Zava BSc1, Christopher
Denton PhD FRCP2, Karen E. Porter PhD1, Justin F. X. Ainscough PhD1, Mark J. Drinkhill
PhD1, Neil A. Turner PhD1
1Division of Cardiovascular and Diabetes Research, and Multidisciplinary Cardiovascular
Research Centre, Leeds Institute of Cardiovascular and Metabolic Medicine, School of
Medicine, University of Leeds, Leeds, LS2 9JT, UK;
2Centre for Rheumatology, University College London Division of Medicine, Royal Free
Campus, Rowland Hill Street, London, NW3 2PF, UK.
Short title: Fibroblast p38 regulates cardiac hypertrophy via IL-6
Corresponding Author: Dr Neil A. Turner, Division of Cardiovascular & Diabetes Research,
LIGHT Laboratories, Clarendon Way, University of Leeds, Leeds LS2 9JT, UK. Tel:
+44(0)113-3434817. E-mail: n.a.turner@leeds.ac.uk
Word count: 6980
2ABSTRACT
Rationale: The p38 family of stress-activated MAP kinases have important functions in
cardiac signalling and in cardiomyocyte hypertrophy following myocardial injury or stress.
However the specific role of cardiac fibroblast p38 in hypertrophic remodelling of the heart in
vivo is unknown.
Objective: To elucidate the role of p38 in cardiac fibroblasts in modulating cardiac
hypertrophic remodelling.
Methods and Results: A fibroblast-specific tamoxifen-inducible p38 knockout mouse model
was developed by crossing Col1a2-Cre-ER(T) mice with floxed p38 (Mapk14) mice.
Tamoxifen-injected male mice (Cre-negative control or Cre-positive knockout) underwent
myocardial injury at 10-12 weeks of age by subcutaneous mini-osmotic pump infusion of the
β-adrenergic receptor agonist isoproterenol (ISO) or saline control for 2 weeks. Cardiac
function was assessed by Millar conductance PV catheter and heart samples analysed for
mRNA and microRNA expression by real-time RT-PCR. ISO infusion in control mice promoted
overt cardiac hypertrophy and dysfunction: increased end systolic volume, reduced ejection
fraction, increased heart weight/tibia length ratio, upregulation of myocyte hypertrophy
markers (ANF, β-MHC) and up-regulation of hypertrophy-associated microRNAs. Fibroblast-
specific p38 knockout mice exhibited protection against myocardial injury, with ISO-induced
alterations in cardiac function, histology and molecular markers all being attenuated. In vitro
mechanistic studies revealed a role for p38-dependent secretion of the cardiomyocyte
hypertrophy-inducing factor interleukin-6 (IL-6) from cardiac fibroblasts in response to cardiac
damage-associated molecular patterns.
Conclusions: p38 in cardiac fibroblasts plays a key role in driving cardiomyocyte
hypertrophy and cardiac dysfunction via a mechanism involving paracrine fibroblast-to-
myocyte IL-6 signalling.
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3Non-standard Abbreviations and Acronyms
CO Cardiac output
DAMPs Damage-associated molecular patterns
EDP End diastolic pressure
EDV End diastolic volume
EF Ejection fraction
ESV End systolic volume
ESP End systolic pressure
Fb-p38 KO Tamoxifen-inducible fibroblast-specific p38 knockout mouse line
FGF2 Fibroblast growth factor 2
HR Heart rate
IGF-1 Insulin-like growth factor-1
IL-6 Interleukin-6
ISO Isoproterenol
LV Left ventricular
Mapk14 Gene encoding p38 protein
MHC Myosin heavy chain
PV Pressure-volume
SV Stroke volume
TGF-β Transforming growth factor-β 
WGA Wheat germ agglutinin
4INTRODUCTION
The p38 family of stress-activated MAP kinases plays an important role in cardiac signalling
and is activated in both acute and chronic cardiac pathologies including myocardial infarction,
left ventricular (LV) remodelling, contractile dysfunction, arrhythmia and heart failure.1-4 A host
of pre-clinical studies have demonstrated that p38 MAPK inhibition can reduce the adverse
consequences of cardiac injury or stress.1-4
There are four known p38 MAPK subtypes (, β, , ); p38 and p38β share sequence
homology and unlike p38 and p38, are inhibited by the pyrindinyl imidazole class of p38
inhibitors (e.g. SB203580). The expression and function of individual p38 subtypes varies in a
cell- and tissue-dependent manner; p38 is the most highly expressed subtype in the heart,
with lower levels of p38 and p38, and little or no expression of p38β.5-7 p38 knockout mice
are not viable due to an essential role for this subtype in placental development.8
Many studies on p38 MAPK in the heart have explored the role of the  and β subtypes.1-4
In vitro experiments involving ectopic over-expression of p38/β suggested a role for the β
rather than the  subtype in stimulating cardiomyocyte hypertrophy.9,10 However, the relatively
low endogenous expression of p38β in human,5 mouse6 and rat7 hearts compared with p38
and other p38 subtypes, may question the physiological importance of these findings. Several
studies in a variety of species and cardiac injury models have reported that pharmacological
p38/β inhibition is effective at reducing cardiac hypertrophy.11 One such study demonstrated
that a p38-selective inhibitor was protective against isoproterenol (ISO)-induced cardiac
hypertrophy and dysfunction in rats;12 suggesting it is p38 rather than p38β that is important
in mediating cardiac hypertrophy in vivo. However, when p38 has been selectively inhibited
in cardiomyocytes in vivo (using either cardiomyocyte-specific knockout or dominant negative
approaches) there was no apparent benefit on cardiac or cardiomyocyte hypertrophy and
some studies reported worsened hypertrophy.13-16 Similar negative results were obtained with
cardiomyocyte-restricted expression of dominant negative p38β.14 Thus, there is clear discord
between pharmacological and cardiomyocyte-specific targeted genetic approaches in
ascribing roles to p38 and p38β in cardiac hypertrophy.
A possible unifying explanation for these disparate in vivo data relates to cell type
specificity. Whilst pharmacological inhibitors and global knockout models affect all cell types,
“cardiac-specific” alpha-myosin heavy chain (MHC)-driven genetic models (knockout or
dominant negative) specifically target cardiomyocytes. It has been widely assumed that the
inhibitory effects of p38 inhibitors on cardiac hypertrophy are due directly to inhibition of
cardiomyocyte p38 activity, with little attention given to other cardiac cell types.
Cardiac fibroblasts are one of the most prevalent non-myocyte cell populations in the heart;
accounting for between one-quarter and two-thirds of cardiac cells depending on the
species.17,18 Although traditionally viewed solely in relation to extracellular matrix remodelling,
cardiac fibroblasts are now acknowledged as being important nodal regulators of multiple
aspects of cardiac function under both physiological and pathophysiological conditions.19-21
Recent evidence has established a critical role for fibroblasts in inducing cardiomyocyte
hypertrophy through paracrine secretion of growth factors and other signalling molecules.22,23
To address the role of fibroblast p38 in modulating cardiac hypertrophy in vivo, we
developed an inducible fibroblast-specific p38 knockout mouse model and investigated
cardiac function and molecular changes in a chronic β-adrenergic receptor activation model
of cardiac hypertrophy. Our data provide evidence that cardiac fibroblast p38 is integral to
ISO-induced cardiac hypertrophy and dysfunction due to a paracrine signalling mechanism
involving fibroblast secretion of the cardiomyocyte hypertrophy-inducing factor interleukin-6
(IL-6).
5METHODS
Animal welfare
All animal procedures were carried out in accordance with the Animal Scientific Procedures
Act (UK) 1986 under UK Home Office authorisation following review by the University of Leeds
Animal Welfare and Ethical Review Committee. Mice were maintained in GM500 individually
ventilated cages (Animal Care Systems) at 21°C, 50-70% humidity, 12/12 h light/dark cycle
with Pure-o’Cel paper bedding (Datesand) and ad libitum access to water and RM1 diet
(Special Diets Services).
Generating an inducible fibroblast-specific p38 knockout mouse model
A tamoxifen-inducible fibroblast-specific p38 knockout mouse line (Fb-p38 KO) was
established by crossing C57BL/6 mice expressing fibroblast-specific tamoxifen-inducible Cre
recombinase (Col1a2-Cre-ER(T))24,25 with C57BL/6 mice expressing a modified p38
(Mapk14) gene with exons 2-3 flanked by loxP sites26 (Fig. 1A, Suppl. Fig. 1). The Col1a2-
Cre-ER(T) line induces gene deletion in cardiac (and other) fibroblasts without effects on
cardiomyocytes, endothelial cells, smooth muscle cells, progenitor cells, pericytes or
macrophages.27,28 Fb-p38 KO mice (i.e. Cre-positive Mapk14fl/fl) were compared alongside
control littermates (i.e. Cre-negative Mapk14fl/fl) for the main experimental protocols. Mice
were injected with tamoxifen dissolved in corn oil (100 mg/kg/day i.p. for 5 consecutive days)
at 3 weeks of age to induce Cre activity and facilitate loxP-directed deletion.
Genotyping PCR
DNA was extracted from ear notch samples using a phenol:chloroform extraction method after
incubation of samples overnight at 37°C in lysis buffer (50 mmol/L EDTA, 10 mmol/L Tris-HCl
pH 8.0, 1% (w/v) SDS, 0.5 mg/mL proteinase K). End-point PCR (94ºC 3 min, 35 cycles x
[94ºC 30 s, 62ºC 30 s, 72ºC 30 s], 72ºC 3 min, 4ºC hold) was performed with specific primer
pairs (see Suppl. Table 1 for details) and agarose gel electrophoresis was used to identify the
presence of Cre, floxed Mapk14 and deletion of Mapk14 exons 2-3.
Cardiac fibroblast culture
Cardiac fibroblasts were cultured from mouse hearts by collagenase digestion, as described
previously.29 Briefly, hearts were thoroughly washed in phosphate buffered saline and minced
prior to digestion with Worthington Type II collagenase (2 mg/mL, 600 IU/mL) at 37oC for 90
min with regular shaking. Cells were pelleted by centrifugation and washed twice in culture
medium before seeding into 3 wells of a 6-well tissue culture plate (one each for DNA, RNA
and protein analysis) or a 25cm2 cell culture flask for subsequent passaging. Non-adherent
cells were removed after 30 min and cells incubated with full growth medium (Dulbecco’s
modified Eagle’s medium+10% foetal calf serum). Cells were washed twice with phosphate
buffered saline the next day to remove residual non-adherent cells and fresh growth medium
added. Primary cultures of cells were analysed for p38 expression 4 days after plating.
Passage 1 cells were used for in vitro mechanistic studies.
Cardiac cell fractionation
Collagenase-digested hearts were filtered through a 30 m MACS smart strainer (Miltenyi
Biotec) to remove cardiomyocytes. Non-myocytes were separated into two fractions; ‘non-
fibroblasts’ (endothelial cells and leukocytes) and ‘fibroblasts’ using a cardiac fibroblast
magnetic antibody cell separation kit (MACS; Miltenyi Biotec). RNA was extracted from cell
fractions and qRT-PCR used to quantify mRNA for cell type-specific marker genes and p38.
Gene expression levels were compared with those obtained from collagenase-digested whole
heart.
RNA extraction, cDNA synthesis and real-time RT-PCR
RNA was extracted from cultured/fractionated cells using the Aurum RNA extraction kit
(BioRad) or from heart tissue using TRI reagent (Sigma-Aldrich). cDNA was synthesised using
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7500 System with gene expression mastermix and specific Taqman primer/probe sets from
Applied Biosystems (details in Suppl. Table 2). Data are expressed relative to Gapdh
housekeeping gene mRNA expression using the 2-ΔCT method.
Western blotting
Western blotting was performed as described previously30 using Cell Signaling Technology
antibodies for p38 (#9228), phospho-p38 (#9211) and phospho-HSP27 (#2401).
Horseradish peroxidase-conjugated anti-mouse and anti-rabbit secondary antibodies and ECL
detection reagent were from GE Healthcare. Monoclonal β-actin antibody (ab8226; Abcam)
was used as a loading control.
Isoproterenol infusion
Mini-osmotic pumps (Alzet 1002) were implanted subcutaneously in isofluorane-
anaesthetised mice (control and Fb-p38 KO) as described previously31 and saline or ISO (30
mg/kg/day) infused for 14 days. Pumps were removed under isofluorane anaesthesia before
recovery and analysis of cardiac function 1 week later. Group sizes were: control-saline
(n=11), control-ISO (n=9), Fb-p38 KO-saline (n=8) and Fb-p38 KO-ISO (n=11).
Measurement of cardiac function and cardiac weight index
Physiological measurements of cardiac function were obtained at the end of the experimental
period by Millar conductance pressure-volume (PV) catheter analysis as described
previously.32 Briefly, mice were anaesthetised with isofluorane and body temperature
maintained with a heating pad before inserting a 1.4 F miniature PV catheter (PVR-1045/SPR-
839; Millar) into the left ventricle via the right carotid artery and ascending aorta. Data were
collected via an MPVS-300 pressure volume system (Millar) and PV loop analysis was
performed using Chart 8 Pro software (AD Instruments). 7 animals (18%) did not survive the
procedure resulting in final group sizes of: control-saline (n=9), control-ISO (n=8), Fb-p38
KO-saline (n=7) and Fb-p38 KO-ISO (n=8). The investigator performing the PV
measurements was blinded to the genotype of the animals.
Hearts were subsequently excised, cleaned, atria removed and ventricles weighed. Tibia
were also collected, cleaned and measured. Cardiac weight index was calculated as
ventricular weight to tibia length ratio. Ventricles were snap frozen and stored at -80oC for
further analysis.
Histology
Cryosections of ventricular tissue (8 m thickness) were mounted on poly-L-lysine-coated
slides and fixed with 4% paraformaldehyde for 20 min. Sections were incubated with
rhodamine-labelled wheat germ agglutinin (WGA, 1:1000; Vector Laboratories) for 2 h,
washed with phosphate buffered saline, then mounted using VectaShield containing DAPI
(Vector Laboratories). Confocal images were captured using a Zeiss LSM700 fluorescence
microscope with X40 objective and ZEN 2.1 SP1 software (Zeiss). Cardiomyocyte cross-
sectional areas were averaged from 7 or 8 animals per group, with 10 fields of view analysed
per animal using Corel PaintShop Pro X8 and Image J (NIH). Measurements were performed
in a blinded fashion and by two independent observers.
MicroRNA RT-PCR array
cDNA was synthesised from 4 cardiac RNA samples for each of three groups (control-saline,
control-ISO, Fb-p38 KO-ISO) using miScript II Reverse Transcription kit (Qiagen) before
performing a miScript miRNA PCR Array (MIMM-113ZA; Qiagen) using the ABI-7500 Real-
Time PCR System. This SYBR-Green based array enabled expression levels of 84
cardiovascular-related miRNAs to be analysed. Data are expressed relative to the geometric
mean of the 6 normalisation controls included on the array (SNORD61, SNORD68,
SNORD72, SNORD95, SNORD96A, RNU6-2) using the 2-ΔCT method.
7Preparation of cardiac DAMPs
Murine hearts were excised, cleaned and subjected to freeze/thaw and homogenisation in 2
ml phosphate buffered saline per heart to disrupt tissue and cellular structure. The resultant
homogenate was centrifuged to remove debris and the supernatant filter-sterilised before
aliquoting for long-term storage at -80oC.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 6 Software (www.graphpad.com).
All data are mean values ± SEM. n represents the number of separate animals investigated
or the number of separate hearts from which cells were isolated. Data were analysed by
Student’s t-test or one-way ANOVA with Sidak post hoc test, as appropriate. P<0.05 was
considered statistically significant.
RESULTS
Generation of mice with inducible fibroblast-specific deletion of p38
To investigate the role of cardiac fibroblast p38 in hypertrophic cardiac remodelling, we
generated an inducible fibroblast-specific p38 knockout mouse line. This involved crossing
mice expressing fibroblast-specific tamoxifen-inducible Cre recombinase (Col1a2-Cre-
ER(T))24,25 with mice expressing a modified p38 gene (Mapk14) with exons 2-3 (coding for
the ATP-binding site of the kinase domain) flanked by loxP sites26 (Fig. 1A, Suppl. Fig. 1).
Tamoxifen injection at 3 weeks of age induced Cre activity and resultant Cre-lox directed
deletion of Mapk14 exons 2-3 (Fig. 1A). Deletion was confirmed initially by PCR genotyping
of ear notches, i.e. dermal fibroblasts (Fig. 1B), and confirmed in cell cultures. Primary cultures
of cardiac fibroblasts from hearts of Fb-p38 KO mice had a 50% reduction of Mapk14 mRNA
(Fig. 1C) and p38 protein (Fig. 1D,E) compared with cells from control mice. Knockdown in
freshly isolated cardiac cells was investigated by digesting hearts with collagenase before
separating non-myocytes into two distinct cell fractions using a magnetic antibody cell
separation technique. Endothelial cells (Pecam1-positive) were separated into Fraction 1
along with leukocytes, whereas fibroblasts (Ddr2, Pdgfra, Col1a1, Col1a2-positive) were
separated into Fraction 2 (Fig. 1F). Evaluation of relative Gapdh mRNA expression in the two
fractions indicated that approximately 64% of non-myocytes were present in Fraction 1 and
32% in Fraction 2, in agreement with recent comprehensive studies on the cellular composition
of the murine heart.33 A 65% reduction in Mapk14 mRNA levels was observed in the fibroblast-
enriched fraction 2 from Fb-p38 KO mice compared with control mice (Fig. 1G). No reduction
in Mapk14 mRNA levels was evident in the endothelial cell/leukocyte-enriched fraction 1 (Fig.
1G), confirming the fibroblast-specific nature of the deletion. The extent of p38 depletion that
we observed in isolated fibroblasts (65%) is similar to that reported in previous studies using
the Col1a2-Cre-ER(T) approach.27
Fibroblast-specific p38 knockout protects against catecholamine-induced cardiac
hypertrophy
The effect of fibroblast-specific p38 knockout was investigated in a chronic β-adrenergic
receptor activation model of cardiac hypertrophy. Control or Fb-p38 KO mice were injected
with tamoxifen at 3 weeks of age, and then at 10-12 weeks of age were implanted with osmotic
mini-pumps delivering saline or ISO (30 mg/kg/day) for 14 days (Fig. 2A). Pumps were
removed and the animals left for 1 more week before analysing cardiac function by PV catheter
recordings (Fig. 2B). In control mice, ISO induced characteristic cardiac dysfunction and
dilatation as measured by several haemodynamic indices, including reduced ejection fraction
(EF; control=70.6±4.0, ISO=43.7±3.6 %; P<0.001), reduced stroke volume (SV;
control=18.0±1.0, ISO=13.0±1.8 L; P<0.05), reduced cardiac output (CO;
control=10509±744, ISO=7476±1028 L/min; P=0.06) and increased end systolic volume
(ESV; control=8.9±1.3, ISO=17.7±1.8 L; P<0.001) (Fig. 2C). Fb-p38 KO mice exhibited
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treatment did not significantly affect EF (ISO=63.9±4.8 %), SV (ISO=17.6±1.4 L), CO
(ISO=10940±1018 L/min) or ESV (ISO=11.2±2.0 L) (Fig. 2C).
Cardiac hypertrophy was investigated by measuring cardiac weight index (ventricular
weight / tibia length ratio), expression of hypertrophy-associated foetal cardiomyocyte genes
and cardiomyocyte cross-sectional area (Fig. 3). In control mice, ISO induced significant
increases of 9% in cardiac weight index (Fig. 3A), 4.6-fold in atrial natriuretic factor (Nppa)
mRNA expression, 8.6-fold in β-MHC (Myh7) mRNA expression (Fig. 3B) and 43% in
cardiomyocyte cross-sectional area (Fig. 3C,D). Strikingly, Fb-p38 KO mice showed very
little evidence of ISO-induced cardiac hypertrophy measured by any of these methods (Fig.
3A-D). Investigation of fibrotic markers revealed no overt effect of ISO on collagen (Col1a1 or
Col3a1) mRNA expression in control hearts 3 weeks after initiation of ISO infusion and there
were no differences in collagen expression between control mice and Fb-p38 KO mice (Fig.
3B).
A focused miRNA array was employed to investigate the effect of ISO on selected
cardiovascular miRNAs and the influence of fibroblast-specific p38 knockout (Fig. 4). RNA
samples prepared from hearts of saline-infused control mice were compared with those of
ISO-infused control mice and ISO-infused Fb-p38 KO mice (4 hearts per group) and
expression levels of 84 cardiovascular miRNAs evaluated (see Suppl. Table 3 for full data
set). The 10 most highly expressed miRNAs in control hearts from saline-infused animals
included miR-1a, miR-126a, miR-24 and multiple members of the miR-23, miR-26 and miR-
30 families (Fig. 4A). 12 of the 84 miRNAs studied were reproducibly increased in hypertrophic
hearts from ISO-infused mice compared with hearts from saline-infused mice (miR-21a, 24,
27a/b, 29a/c, 140, 199a, 208a/b, 214 and 224), and two miRNAs were decreased in ISO
hearts compared with saline hearts (miR-30d and 150) (Fig. 4B). Fibroblast-specific p38
knockout opposed the effects of ISO on some of these miRNAs; namely miR-208b, 21a, 214,
224 and 30d (Fig. 4C). P38 knockout also induced miR-328 expression, although it was not
modulated by ISO; suggesting negative regulation of this miRNA by fibroblast p38 (Fig. 4C).
Cardiac fibroblast p38 is required for damage-induced secretion of the cardiomyocyte
hypertrophy-inducing factor IL-6
Cardiac fibroblasts have been shown to play a critical role in stimulating cardiomyocyte
hypertrophy through paracrine secretion of hypertrophic growth factors, including fibroblast
growth factor 2 (FGF2), insulin-like growth factor-1 (IGF-1) and transforming growth factor-β
(TGF-β).22,23 We surmised that IL-6 may also play a similar role. Our hypothesis was that
cardiac fibroblast p38 could be important for secretion of such cardiomyocyte hypertrophy-
inducing factors in our model and that this would explain the ability of cardiac fibroblast p38
deletion to improve cardiac hypertrophy after ISO infusion.
Firstly we investigated whether ISO could directly activate p38 MAPK in cultured cardiac
fibroblasts and then whether it could induce myocyte hypertrophy-inducing factors (FGF-2,
IGF-1, TGF-β1 and IL-6) in a p38-dependent manner. Although ISO directly activated
fibroblast p38 (Fig. 5A), it was unable to stimulate expression of any of the hypertrophy-
inducing genes tested (Fig. 5B).
We next investigated whether ISO could be modulating fibroblast function indirectly by
inducing cardiac damage, resulting in release of damage-associated molecular patterns
(DAMPs) and fibroblast activation.20 To mimic this in vitro, we prepared cardiac DAMPs by
freeze-thawing and homogenising mouse heart tissue. This cardiac DAMPs preparation
activated p38 when added to cultured cardiac fibroblasts (Fig. 5A). Cardiac DAMPs did not
modulate Fgf2 mRNA levels, but strongly stimulated Il6 mRNA expression by >10-fold and
increased Tgfb1 mRNA levels by 50% after 6 h (Fig. 5B). The DAMPs preparation had the
opposite effect on Igf1 mRNA levels, decreasing them by 50% (Fig. 5B). Further investigation
into the time course of these effects revealed that the increase in Il6 and Tgfb1 mRNA
expression returned to basal levels within 24 h, whereas the reduction in Igf1 levels was
maintained for at least 48 h (Fig. 6A). Despite the relatively transient nature of Il6 mRNA
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protein secretion in response to cardiac DAMPs, with peak levels of >10 ng/mL maintained for
24-48 h after the initial stimulus (Suppl. Fig. 2). The p38 MAPK inhibitor SB203580 (Merck)
was used to evaluate the importance of p38 in mediating DAMPs-induced changes in
hypertrophic gene expression. SB203580 prevented p38 MAPK downstream signalling as
expected (Fig. 6B) and significantly reduced DAMPs-induced Il6 mRNA expression and
protein secretion (Fig. 6C, 6D). In contrast, the p38 inhibitor had no effect on DAMPs-induced
expression of Tgfb1 or Igf1 mRNA (Fig. 6C). Together these data indicate that cardiac DAMPs
can stimulate IL-6 transcription and protein secretion in a p38-dependent manner; a
mechanism that likely explains our in vivo observations.
DISCUSSION
Our study demonstrated that fibroblast-specific knockout of p38 negates the deleterious
effects of chronic β-adrenergic receptor stimulation on cardiac hypertrophy and function. 
Specifically, our in vivo experiments revealed that fibroblast-specific p38 knockout prevented
the ability of chronic ISO infusion to reduce EF, increase ESV, increase ventricular weight/tibia
length ratio, upregulate myocyte hypertrophy markers (atrial natriuretic factor, β-MHC),
upregulate pro-hypertrophic miRNAs and downregulate anti-hypertrophic miRNAs. Our
supporting in vitro experiments indicated a key role for p38 in mediating DAMPs-induced
secretion of the cardiomyocyte hypertrophy-inducing factor IL-6 from cardiac fibroblasts. Our
study therefore reveals that cardiac fibroblast p38 is important for regulating cardiomyocyte
hypertrophy through paracrine fibroblast-to-myocyte signalling involving IL-6 secretion (Fig.
6E).
Despite nearly two decades of study, the precise individual roles of p38 and p38β in
modulating cardiomyocyte hypertrophy remain unclear, with seemingly contradictory
outcomes reported.2,3,11 Results from in vitro ectopic over-expression studies of individual p38
subtypes in cardiomyocytes are at odds with cardiomyocyte-targeted in vivo genetic inhibition
studies, yet pharmacological p38 inhibition appears effective at reducing cardiac
hypertrophy. Our data offer a unifying explanation by uncovering a role for cardiac fibroblast
p38 in modulating cardiomyocyte hypertrophy in vivo.
Many stimuli that cause LV hypertrophy (e.g. catecholamines, Ang II, pressure overload)
are direct inducers of cardiomyocyte cellular hypertrophy in vitro, and this has been assumed
to underlie their hypertrophic action on the heart. However, this concept has been challenged
by several recent studies showing that fibroblasts act as primary integrators of hypertrophic
stimuli in the intact heart.22,23,34 A number of paracrine signalling molecules have been
identified through which fibroblasts can modulate cardiomyocyte hypertrophy, including FGF2,
IGF-1 and TGF-β. Additionally, IL-6 may act in this manner as this cytokine is actively secreted 
from cardiac fibroblasts in response to β-adrenergic receptor stimulation or Ang II,19 is able to
directly induce cardiomyocyte hypertrophy35 and IL-6 knockout mice are protected against LV
hypertrophy in response to noradrenaline, Ang II or pressure overload.35-37
The miRNA microarray identified several highly expressed miRNAs in control murine heart
tissue, with miR-1, 126a and 30c being the most abundant. Twelve of the 84 miRNAs studied
were reproducibly increased, and two were decreased, in hypertrophic hearts from ISO-
infused mice compared with hearts from saline-infused mice. Many of these miRNAs have
been shown to be modulated similarly in other reports on mouse and rat models of cardiac
hypertrophy.38-42 We identified five miRNAs that were significantly regulated by ISO in control
mice but not in Fb-p38 KO mice (miR-208b, 21a, 214, 224 and 30d), suggesting relevance
to the cardioprotective effect of fibroblast-specific p38 knockout. MiR-208b lies within an
intron of the β-MHC gene so its increase would be expected given the increase in β-MHC
(Myh7) mRNA expression in ISO hearts. Interestingly, two of the other miRNAs (miR-21a and
miR-214) have been shown to positively regulate IL-6 secretion in macrophages and
fibroblast-like ligamentum flavum cells.43,44 These microRNAs may play similar roles in cardiac
fibroblasts, contributing to the paracrine IL-6 hypertrophic effect we discovered. We identified
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just one miRNA (miR-328) that was elevated in ISO-infused p38 KO hearts compared with
ISO-infused control hearts, suggesting negative regulation by fibroblast p38. Indeed, miR-
328 has been shown to be negatively regulated by p38 MAPK in human osteosarcoma cells.45
Whilst our study was being finalised, several new reports emerged that also support a
critical role for cardiac fibroblast p38 in modulating cardiac remodelling. Firstly, a non-biased
transcriptomic approach identified cardiac fibroblast ATF3 as being cardioprotective in HF
models; and fibroblast p38 MAPK was identified as the downstream molecule responsible for
profibrotic and hypertrophic effects in fibroblast-specific ATF3 KO mice (Col1a2-Cre-ER(T)
model).46 Secondly, global knockdown of MK5 (a p38 substrate localised to cardiac fibroblasts
but not myocytes) was associated with the attenuation of both hypertrophy and cardiac
dysfunction in response to chronic pressure overload.47 Thirdly, it was reported that inducible
fibroblast-selective knockdown of p38 (using Tcf21- and Postn-directed Cre KO mouse
models) could reduce myofibroblast differentiation and fibrosis following ischemic injury or
chronic neurohumoral stimulation.48 Although focused on fibrosis, this latter study also noted
that fibroblast-selective p38 KO reduced cardiac hypertrophy induced by Ang II and
phenylephrine infusion.48 Our study defines a clear hypertrophic role for cardiac fibroblast
p38 and identifies IL-6 as a p38-induced paracrine factor capable of stimulating
cardiomyocyte hypertrophy in this setting. Thus, strong evidence is accumulating that p38 in
cardiac fibroblasts acts as a central mediator of cardiac hypertrophy and fibrosis in a variety
of pathological scenarios, making it an attractive target for therapeutic intervention.
In conclusion, our study reveals an important role for p38, specifically in cardiac
fibroblasts, in stimulating cardiac hypertrophy after chronic β-adrenergic stimulation via an IL-
6 dependent mechanism. These findings help to explain the disparity between the effects of
pharmacological p38 inhibitors and cardiomyocyte-specific knockout/inhibition models for
inhibiting cardiac hypertrophy in vivo. They also further our understanding of the key role that
cardiac fibroblasts play in regulating cardiac hypertrophy and remodelling through paracrine
signalling, and identify the cardiac fibroblast p38 / IL-6 axis as a potential therapeutic target
in this setting.
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FIGURE LEGENDS
Figure 1. Inducible fibroblast-specific deletion of p38 in mouse heart. (A) Schematic diagram
of deletion strategy combining Col1a2-Cre-ER(T) mice with floxed Mapk14 mice. Deletion of
exons 2-3 occurs following tamoxifen injection which activates Cre-ER(T). Red arrowheads
denote position of genotyping primers X, Y and Z (see Suppl. Table 1). (B) Genotyping PCR
showing effective exon 2/3 deletion in ear notch samples from tamoxifen-injected experimental
Cre-positive Mapk14fl/fl mice (E1-2) compared with control Cre-negative Mapk14fl/fl mice (C1-
3). Upper panel: Cre primers (Cre = 408 bp). Lower panel: Mapk14 exon 2/3 floxed/deletion
primers. Deletion (Z+Y) = 411 bp, floxed (X+Y) = 188 bp. M=100 bp ladder. (C) Real-time RT-
PCR analysis of Mapk14 mRNA levels in primary cultures of cardiac fibroblasts from control
Cre-negative Mapk14fl/fl mice (n=6) and Cre-positive Mapk14fl/fl knockout (KO) mice (n=8)
following tamoxifen injection. *P<0.05. (D) Immunoblot analysis of p38 protein in primary
cultures of cardiac fibroblasts from control Cre-positive Mapk14wt/wt (C), heterozygous Cre-
positive Mapk14wt/fl (Het) and experimental Cre-positive Mapk14fl/fl mice (E1-4) following
tamoxifen injection. β-actin loading control. (E) Densitometric analysis of p38 protein
expression relative to β-actin in control, heterozygous (Het) and experimental (KO) cells. (F)
Characterisation of non-myocyte isolated cell fractions from collagenase-digested mouse
hearts (n=7). Fr1 = endothelial cells and leukocytes; Fr2 = cardiac fibroblasts. Bar charts show
qRT-PCR data for mRNA levels of cell type-specific marker genes. Cardiomyocyte marker:
Myh6. Endothelial marker: Pecam1. Fibroblast markers: Ddr2, Pdgfra, Col1a1 and Col1a2. All
data normalised to Gapdh mRNA levels and expressed relative to whole heart. (G) Real-time
RT-PCR analysis of Mapk14 mRNA levels in isolated cell fractions from hearts of control Cre-
negative Mapk14fl/fl mice (n=3) and experimental Cre-positive Mapk14fl/fl knockout (KO) mice
(n=4) following tamoxifen injection. Fr1 = endothelial cells and leukocytes; Fr2 = fibroblasts.
**P<0.01, NS not significant.
Figure 2. Effect of fibroblast-specific p38 knockout on isoproterenol-induced cardiac
dysfunction. (A) Timeline for chronic β-adrenergic receptor activation model of cardiac
hypertrophy. (B) Individual representative PV loops obtained from control and fibroblast-
specific p38 KO mice following infusion with either saline (control, blue) or isoproterenol (ISO,
red). (C) PV conductance catheter data. Individual data and mean ± SEM are shown. Group
sizes: control saline (n=9), control ISO (n=8), KO saline (n=7), KO ISO (n=8). ANOVA with
Sidak post-hoc test: ***P<0.001, *P<0.05, NS not significant.
Figure 3. Effect of fibroblast-specific p38 knockout on isoproterenol-induced cardiac
hypertrophy. Control or Fb-p38 KO mice were injected with tamoxifen and mini-osmotic
pumps implanted for delivery of saline or ISO as in Fig. 2A. Pumps were removed and heart
tissue collected 1 week later. All data are mean ± SEM. ANOVA with Sidak post-hoc test:
***P<0.001, *P<0.05, NS not significant. (A) Ventricular weight/tibia length ratio (cardiac weight
index) from animals used in PV analysis. Group sizes: control saline (n=9), control ISO (n=8),
KO saline (n=7), KO ISO (n=8). (B) Real-time RT-PCR analysis of mRNA levels for
cardiomyocyte hypertrophy markers atrial natriuretic factor (Nppa) and β-myosin heavy chain
(Myh7) and fibrosis markers Col1a1 and Col3a1. Group sizes: control saline (n=11), control
ISO (n=9), KO saline (n=8), KO ISO (n=11). (C) Representative images of wheat germ
agglutinin (WGA)-labelled heart sections used to determine myocyte cross-sectional area.
Scale bar = 20 m. (D) Mean cardiomyocyte size (cross-sectional area) determined from
WGA-stained images. Group sizes: control saline (n=8), control ISO (n=7), KO ISO (n=8).
Figure 4. Effect of fibroblast-specific p38 knockout on isoproterenol-induced miRNA
expression. Control or Fb-p38 KO mice were injected with tamoxifen and infused with saline
or ISO as described in Fig. 2A and Fig. 3 legends. Heart tissue was collected 1 week after
removal of mini-osmotic pumps and expression levels of 84 cardiovascular miRNAs
determined using a real-time RT-PCR array. Group sizes: n=4. See Suppl. Table 3 for full data
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set. (A) List of the 22 most highly expressed miRNAs in control hearts from saline-infused
mice. Data are mean expression levels (2-ΔCT) relative to array normalisation controls. (B)
MiRNAs increased or decreased following ISO infusion. **P<0.01, *P<0.05 for effect of ISO
(unpaired t-test). (C) MiRNAs modulated by fibroblast-specific p38 knockout. ANOVA with
Sidak post-hoc test: ***P<0.001, **P<0.01, *P<0.05, NS not significant compared with control
saline group. #P<0.05 compared with control ISO group. Data expressed relative to array
normalisation controls.
Figure 5. Effects of isoproterenol and cardiac DAMPs on p38 activation and expression of
hypertrophy-inducing factors in cultured cardiac fibroblasts. (A) Western blotting of
phosphorylated (activated) p38 and total p38 expression showing time course of response
to 5 mol/L ISO, concentration response to 0.1-10 mol/L ISO after 15 min and time course
of response to cardiac DAMPs. Blots representative of 3 separate experiments. (B) Real-time
RT-PCR data showing effect of ISO (5 mol/L, 6 h, n=8) or cardiac DAMPs (6 h, n=12) on
mRNA expression of Fgf2, Il6, Tgfb1 and Igf1. Data expressed as % Gapdh mRNA levels.
***P<0.001, **P<0.01 (paired ratio t-test).
Figure 6. Role of p38 in DAMPs-modulated expression of hypertrophy-inducing genes in
cardiac fibroblasts. (A) Real-time RT-PCR showing time course of effect of DAMPs on
expression of Il6, Tgfb1 and Igf1. **P<0.01, *P<0.05 (n=3). (B) Western blot showing DAMPs-
induced phosphorylation of HSP27 and p38 after 20 min and inhibition by 10 mol/L
SB203580. Total p38 expression included as loading control. Blots representative of 3
separate experiments. (C) Real-time RT-PCR data showing effect of 10 mol/L SB203580 or
DMSO vehicle control on DAMPs-induced expression of hypertrophy-inducing genes after 6
h (n=9). ANOVA with Sidak post-hoc test: ***P<0.001, **P<0.01, *P<0.05, NS not significant.
Data normalised to Gapdh mRNA levels and expressed relative to control. (D) ELISA showing
effect of 10 mol/L SB203580 or DMSO vehicle control on DAMPs-induced IL-6 secretion after
6 h (n=9). ANOVA with Sidak post-hoc test: *P<0.05, NS not significant. (E) Schematic
depicting role of fibroblast p38 in modulating cardiomyocyte hypertrophy. DAMPs = damage-
associated molecular patterns; IL-6 = interleukin-6.
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SUPPLEMENTAL MATERIAL LEGENDS
Supplemental Figure 1. Breeding strategy for generating Col1a2-Cre-ER(T) positive
(experimental) and Col1a2-Cre-ER(T) negative (control) Mapk14fl/fl mice.
Supplemental Figure 2. ELISA data showing time course of IL-6 secretion from murine
cardiac fibroblasts stimulated with cardiac DAMPs. Blue filled circles represent DAMPs-
stimulated IL-6 secretion and black filled squares represent basal secretion without addition
of DAMPs (measured up to 6 h only). *P<0.05 compared with time zero (n=3).
Supplemental Table 1. Genotyping primer sequences and predicted PCR product sizes. See
Fig.1A for binding positions of X, Y and Z primers and Fig. 1B for PCR gels.
Supplemental Table 2. Taqman primer/probes used for real-time RT-PCR. Purchased from
Applied Biosystems.
Supplemental Table 3. Effect of fibroblast-specific p38 knockout on isoproterenol-induced
microRNA expression - complete data set. See Fig. 4 legend for experimental details. A01-
G12 = mean expression levels (2-ΔCT) of 84 cardiovascular microRNAs relative to
normalisation controls. H01-H02 = negative controls; H03-H08 = normalisation controls; H09-
H10 = reverse transcription positive controls; H11-H12 = PCR positive controls.
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Supplemental Table 1
Primer target Primer sequence Product size(bp)
Cre (forward)
Cre (reverse)
5’ GCATTACCGGTCGATGCAACGAGTGATGAG 3’
5’ GAGTGAACGAACCTGGTCGAAATCAGTGCG 3’ 408 (Cre)
p38 fl (forward) ‘X’
p38 fl (reverse) ‘Y’
5’ CTACAGAATGCACCTCGGATG 3’
5’ AGAAGGCTGGATTTGCACAAG 3’
121 (wild type)
188 (floxed)
p38 del (forward) ‘Z’
p38 del (reverse) ‘Y’
5’ CCAGCACTTGGAAGGCTATTC 3’
5’ AGAAGGCTGGATTTGCACAAG 3’ 411 (deletion)
Supplemental Table 2
Gene Protein Code
Col1a1 Type 1 collagen 1 chain Mm00801666_g1
Col1a2 Type 1 collagen 2 chain Mm00483888_m1
Col3a1 Type 3 collagen 1 chain Mm01254476_m1
Ddr2 Discoidin domain receptor 2 Mm00445615_m1
Fgf2 Fibroblast growth factor 2 Mm01285715_m1
Gapdh Glyceraldehyde 3-phosphate dehydrogenase Mm99999915_g1
Igf1 Insulin-like growth factor 1 Mm00439560_m1
Il6 Interleukin-6 Mm00446190_m1
Mapk14 p38 Mm00442498_m1
Myh6 -myosin heavy chain Mm00440354_m1
Myh7 β-myosin heavy chain Mm00600555_m1 
Nppa Atrial natriuretic factor Mm01255747_g1
Pdgfra Platelet-derived growth factor receptor A Mm00440701_m1
Pecam1 Platelet and endothelial cell adhesion molecule 1(CD31) Mm01242584_m1
Tgfb1 Transforming growth factor-β1 Mm01178820_m1 
Position Mature ID Control Saline Control ISO KO ISO
A01 mmu-let-7a-5p 1.978162 2.172275 2.041877
A02 mmu-let-7b-5p 0.605095 0.635914 0.668553
A03 mmu-let-7c-5p 1.532619 1.722121 1.680468
A04 mmu-let-7d-5p 1.093911 1.055471 1.085327
A05 mmu-let-7e-5p 0.645167 0.752254 0.711122
A06 mmu-let-7f-5p 2.549444 2.685828 2.68337
A07 mmu-miR-100-5p 0.161577 0.190837 0.195614
A08 mmu-miR-103-3p 0.168501 0.177769 0.20665
A09 mmu-miR-107-3p 0.019813 0.016775 0.021257
A10 mmu-miR-10b-5p 0.057463 0.066269 0.060276
A11 mmu-miR-122-5p 0.001465 0.001835 0.001801
A12 mmu-miR-124-3p 0.000606 0.00054 0.000723
B01 mmu-miR-125a-5p 2.114928 2.066103 2.071637
B02 mmu-miR-125b-5p 3.91234 4.221776 4.471839
B03 mmu-miR-126a-3p 17.952363 20.449608 22.115827
B04 mmu-miR-130a-3p 0.125548 0.142245 0.183198
B05 mmu-miR-133a-3p 0.246519 0.20525 0.346145
B06 mmu-miR-133b-3p 0.186687 0.170077 0.278785
B07 mmu-miR-140-5p 0.045359 0.069249 0.066466
B08 mmu-miR-142a-3p 0.142558 0.210599 0.30767
B09 mmu-miR-143-3p 1.263261 1.651269 2.050159
B10 mmu-miR-144-3p 0.001251 0.003234 0.008786
B11 mmu-miR-145a-5p 1.315416 1.537097 1.942239
B12 mmu-miR-146a-5p 0.167853 0.192358 0.158373
C01 mmu-miR-149-5p 0.265799 0.248161 0.288919
C02 mmu-miR-150-5p 1.324479 0.916346 1.188492
C03 mmu-miR-155-5p 0.107766 0.078496 0.102379
C04 mmu-miR-15b-5p 0.383261 0.527334 0.484747
C05 mmu-miR-16-5p 2.753326 3.155302 3.654376
C06 mmu-miR-17-5p 0.149944 0.173987 0.190662
C07 mmu-miR-181a-5p 0.058593 0.05478 0.076275
C08 mmu-miR-181b-5p 0.06097 0.054748 0.056639
C09 mmu-miR-182-5p 0.000525 0.000461 0.000501
C10 mmu-miR-183-5p 0.000413 0.000401 0.000279
C11 mmu-miR-185-5p 0.265257 0.216887 0.242893
C12 mmu-miR-18a-5p 0.00868 0.011482 0.013958
D01 mmu-miR-195a-5p 3.226149 3.795757 4.150002
D02 mmu-miR-199a-5p 0.01817 0.044725 0.042824
D03 mmu-miR-1a-3p 70.693992 57.04811 68.262464
D04 mmu-miR-206-3p 0.081044 0.062917 0.080414
D05 mmu-miR-208a-3p 0.016875 0.030677 0.072187
D06 mmu-miR-208b-3p 0.004045 0.012213 0.008761
D07 mmu-miR-21a-5p 2.354904 4.680181 3.506293
D08 mmu-miR-210-3p 0.008243 0.008814 0.010952
D09 mmu-miR-214-3p 0.04237 0.076406 0.060218
D10 mmu-miR-22-3p 0.445459 0.612899 0.83402
D11 mmu-miR-221-3p 0.0641 0.062163 0.075483
D12 mmu-miR-222-3p 0.083211 0.094821 0.095173
E01 mmu-miR-223-3p 0.425817 0.472874 0.365973
2^(-Avg.(Delta(Ct))
D12 mmu-miR-222-3p 0.083211 0.094821 0.095173
E01 mmu-miR-223-3p 0.425817 0.472874 0.365973
E02 mmu-miR-224-5p 0.008408 0.013581 0.01008
E03 mmu-miR-23a-3p 7.999973 9.286721 9.355538
E04 mmu-miR-23b-3p 4.546558 5.77468 5.07496
E05 mmu-miR-24-3p 4.552592 5.973209 6.325244
E06 mmu-miR-25-3p 0.330425 0.356809 0.366763
E07 mmu-miR-26a-5p 5.55294 6.13263 5.966145
E08 mmu-miR-26b-5p 5.321684 5.695079 5.861896
E09 mmu-miR-27a-3p 2.688119 3.598146 3.907551
E10 mmu-miR-27b-3p 1.827181 2.527138 2.481245
E11 mmu-miR-29a-3p 2.030514 2.760202 3.347464
E12 mmu-miR-29b-3p 0.16203 0.17208 0.273372
F01 mmu-miR-29c-3p 2.071333 2.71383 3.550657
F02 mmu-miR-302a-3p 0.000156 0.000131 0.000148
F03 mmu-miR-302b-3p 0.000168 0.000136 0.000145
F04 mmu-miR-30a-5p 4.665472 4.58408 5.335247
F05 mmu-miR-30c-5p 11.472092 11.131246 11.736017
F06 mmu-miR-30d-5p 2.479405 2.091413 2.4688
F07 mmu-miR-30e-5p 4.069234 4.195758 5.148764
F08 mmu-miR-31-5p 0.069383 0.071437 0.073627
F09 mmu-miR-320-3p 0.091621 0.088029 0.104023
F10 mmu-miR-322-5p 0.778961 1.025937 0.967987
F11 mmu-miR-328-3p 0.069698 0.061058 0.084617
F12 mmu-miR-342-3p 0.116092 0.128755 0.120102
G01 mmu-miR-365-3p 0.144937 0.16812 0.159335
G02 mmu-miR-378a-3p 2.601141 2.371442 2.592555
G03 mmu-miR-423-3p 0.028334 0.024852 0.026223
G04 mmu-miR-451a 2.966517 3.46716 5.613137
G05 mmu-miR-486b-5p 0.413167 0.363977 0.426565
G06 mmu-miR-494-3p 0.00124 0.001414 0.001263
G07 mmu-miR-499-5p 0.646546 0.535546 0.626917
G08 mmu-miR-7a-5p 0.017609 0.018226 0.017562
G09 mmu-miR-92a-3p 0.304953 0.340335 0.337351
G10 mmu-miR-93-5p 0.077645 0.089542 0.118528
G11 mmu-miR-98-5p 0.05129 0.062569 0.051151
G12 mmu-miR-99a-5p 1.092071 1.304632 1.489604
H01 cel-miR-39-3p 0.000155 0.000127 0.000138
H02 cel-miR-39-3p 0.000155 0.000127 0.000138
H03 SNORD61 0.476724 0.528432 0.585235
H04 SNORD68 4.458221 4.156111 3.940604
H05 SNORD72 0.410206 0.443319 0.368542
H06 SNORD95 0.639813 0.605386 0.600758
H07 SNORD96A 2.354499 2.192101 2.094829
H08 RNU6-6P 0.650187 0.673129 0.816331
H09 miRTC 0.237416 0.226773 0.282779
H10 miRTC 0.236745 0.245652 0.305355
H11 PPC 6.19832 5.10393 5.24695
H12 PPC 6.160693 5.442311 5.218452
Supplemental Table 3
